Brain natriuretic peptide (BNP) measurement significantly improved accuracy in diagnosing acute heart failure (HF) beyond clinical judgement, electrocardiogram (ECG), and X-ray. Two years later, BNP measurement in the emergency room was found to speed up correct diagnosis and to reduce time to discharge and costs in such patients. 2 One year later, the PRIDE study revealed that the Nterminal part of the precursor hormone (NT-proBNP) is equally helpful to diagnose acute HF in the emergency setting. 3 Many studies confirmed these findings, and guidelines consider BNP or NT-proBNP as useful to improve diagnosis and management of HF in the acute setting. 4 Moreover, BNP and NT-proBNP are helpful in the prognostic assessment of chronic HF 5 and may even help to guide therapy in outpatient HF care. 6 As a consequence, BNP and NT-proBNP measurements have been widely adopted in clinical practice.
However, measuring BNP or NT-proBNP has limitations, not only in the chronic, but also in the acute setting. Thus, diagnostic value is particularly high if levels of these peptides are at their extremes, leaving the physician with a grey zone of uncertainty. 4 Low levels help to exclude acute HF, particularly in untreated patients or if levels remain unchanged or decrease during episodes of dyspnoea, although there are exceptions that need to be considered. 7 If levels are very high, the likelihood of acute HF is also high, but again there are circumstances that may result in high levels not related to HF. 8 In contrast to the initial assumption, BNP and NT-proBNP levels may be influenced by various factors unrelated to cardiac wall stress which renders interpretation more complex. Levels are higher in women, elderly patients, and those with concomitant renal failure, and lower in obese patients, but they are also influenced by other (neuro-)hormones, inflammation, ischaemia, and drugs. 8 The prognostic value of BNP and NT-proBNP in hospitalized patients has important limitations unless they are measured not only at admission, but also at discharge, 9 whereas they are a relatively poor indicator at initial presentation. 10 Various other biomarkers have been tested in different settings of cardiovascular disease including patients presenting with acute dyspnoea. 11 However, only a minority of them are considered to be sufficiently supported by trial results to be clinically useful in cardiovascular diseases at present ( Figure 1 ). 12 Nevertheless, this large variety shows the clinical need for new, better biomarkers or a stratified combination of biomarkers to improve clinical judgement in different settings. In patients presenting with acute dyspnoea, this is of particular importance because of the poor prognosis and difficulties in properly assessing patients at risk. An analysis of some of these new biomarkers in the PRIDE (Pro-BNP Investigation of Acute Dyspnoea in the Emergency Department) study cohort has now been reported. 13 The authors focused in particular on mid-regional peptides of neurohormones that play an important role in the pathophysiology of HF and that are known to be elevated in patients with acute dyspnoea. 10 To a large extent, Shah et al. 13 are able to confirm previous findings of the BACH study, where mid-regional pro-atrial natriuretic peptide (MR-proANP) was found to be of similar diagnostic value to BNP and NT-proBNP, and mid-regional pro-adrenomedullin (MR-proADM) to be of superior prognostic value. 10 Confirmatory studies are important since the diagnostic value of biomarkers may differ significantly between different patient groups. For example, the BACH study 10 found somewhat less diagnostic accuracy of BNP testing at the same cut-off value as in the Breathing-Not-Properly trial, 1 and the diagnostic value of NT-proBNP differed considerably between BACH and the present analysis of PRIDE. 10, 13 Still, Shah et al. showed that the diagnostic value of MR-proANP may add to that of NT-proBNP, 13 and both studies found significantly higher prognostic value of MR-proADR compared with BNP and NT-proBNP, respectively. 10, 13 The study by Shah et al. expanded on previous findings in that the authors showed not only short-term prognostic value, but also long-term value over a follow-up of up to 4 years. Interestingly, short-and long-term prognostic value differed between MR-proADM and natriuretic peptides. This might be useful depending on the setting studied and the information required, but additional studies are required to confirm this and to define its potential clinical impact. In addition, it is important to note that, in contrast to the diagnostic value of natriuretic peptides, which are relatively specific for acute HF, the prognostic value of both MR-proADM and natriuretic peptides is not restricted to HF patients as they are rather unspecific markers of poor outcome. 14, 15 The PRIDE analysis additionally investigated the prognostic value of galactin-3 as a biomarker in this setting, but found nothing of relevance. 13 The question, however, remains as to what extent both BACH and the additional analysis of PRIDE may improve care in patients presenting with acute dyspnoea. At present, the potential implications are unfortunately limited. First, the diagnostic value of mid-regional peptides does not seem to be superior to that of well-established BNP and NT-proBNP. Whether an additional diagnostic effect of MR-proANP in the grey zone of BNP/ NT-proBNP measurement 10 or in addition to and independently of BNP/NT-proBNP 13 is clinically meaningful needs to be studied and confirmed in additional large trials. A direct clinical application seems to be hampered as different cut-off values are used to diagnose acute HF in the two trials despite a similar area under the curve (AUC) of MR-proANP. 10, 13 This is of particular concern since different values are already being used for various assays of BNP or NT-proBNP. Adding another type of natriuretic peptide with non-uniform cut-off values will add to the confusion and will hinder an intuitive implementation of MR-proANP in the diagnostic armamentarium of acute dyspnoea. Even more importantly, the clinical consequences beyond the initial diagnosis are not clear. 
